Pricing Log in Create free account
Tuesday 20 October 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

113.25 0.18 +0.16%
Market cap
$23.0B
P/E
13.9×
Fwd P/E
58.4×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Incyte Corporation (INCY) EV/EBITDA

Alert me on EV/EBITDA

As of 19 October 2026, Incyte Corporation (INCY) trades at a EV/EBITDA of 9.7×. Over the past ten years it has ranged from 0.0× (March 2021) to 99,927× (August 2017); the current reading is higher than 23% of that period. That is above the Biotechnology industry median of 0.6× and above the Healthcare sector median of 8.9×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 9.8× (87.91%)
FY2024 81.0× 416.49%
FY2023 15.7× (29.85%)
FY2022 22.3× 3.65%
FY2021 21.6× —
FY2020 0.0× —
FY2019 36.6× (44.28%)
FY2018 65.6× —
FY2017 0.0× —
FY2016 93.7× (53.82%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 9.7× 11.97%
Mar 2026 8.7× (11.43%)
Dec 2025 9.8× 12.30%
Sep 2025 8.7× 2.48%
42 more quarters

Against its own ten years

Low 0.0× High 99,927×
Ten-year median 22.1×
Current reading's percentile 23

EV/EBITDA against peers

Company EV/EBITDA
BNTX BioNTech SE Sponsored ADR compare n/m
INSM Insmed, Inc. compare n/m
ROIV Roivant Sciences Ltd. compare n/m
INCY Incyte Corporation 9.7×
EXEL Exelixis, Inc. compare 14.9×
RPRX Royalty Pharma PLC compare 22.6×
GMAB Genmab A/S Sponsored ADR compare 23.4×
ALNY Alnylam Pharmaceuticals, Inc. compare 27.4×
ASND Ascendis Pharma A/S compare 44.8×
Biotechnology industry median 0.6×
Healthcare sector median 8.9×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on INCY